Advertisement

Effects of Ovarian Tissue Cryopreservation on Primary Ovarian Insufficiency in Girls Undergoing Bone Marrow Transplantation

Published:December 04, 2022DOI:https://doi.org/10.1016/j.jpag.2022.12.001

      Abstract

      Objective

      To determine if removing an ovary for ovarian tissue cryopreservation (OTC) increased rates of primary ovarian insufficiency (POI) in girls undergoing bone marrow transplantation (BMT). Institutional review board approval was obtained from all 3 clinical sites.

      Design

      Multicenter retrospective cohort study

      Setting

      Academic children's hospitals

      Patients

      Females aged 2-21 who underwent BMT with or without OTC from 2010 to 2017.

      Interventions

      None

      Main Outcome Measures

      Rates of POI in girls who underwent OTC vs those who underwent BMT alone as determined by serum markers, presence of menses, or clinical diagnosis.

      Results

      A total of 142 patients were identified, 43 who had OTC and 99 with BMT alone. The rate of POI in girls undergoing OTC was 65% vs 41.8% in those who underwent BMT alone (P = .26).

      Conclusions

      Although this study was not powered to detect a lack of difference, it is reassuring that there does not seem to be a clinically significant increase in POI in patients undergoing OTC.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hamish W
        • Wallace B
        • Anderson RA
        • Irvine DS
        Fertility preservation for young patients with cancer: who is at risk and what can be offered?.
        Lancet Oncol. 2005; 6: 209-218
        • Pascale J
        • Donnez J
        How does bone marrow transplantation affect ovarian function and fertility?.
        Curr Opin Obstet Gynecol. 2012; 24: 164-171
        • Meacham LR
        • Burns K
        • Orwig KE
        • Levine J
        Standardizing risk assessment for treatment-related gonadal insufficiency and infertility in childhood adolescent and young adult cancer: the Pediatric initiative Network risk stratification system.
        J Adolesc Young Adult Oncol. 2020; 9: 662-666
        • Shapira M
        • Raanani H
        • Cohen Y
        • Meirow D
        Fertility preservation in young females with hematological malignancies.
        Acta Haematol. 2014; 132: 400-413
        • Logan S
        • Perz J
        • Ussher J
        • et al.
        Clinician provision of oncofertility support in cancer patients of a reproductive age: a systematic review.
        Psychooncology. 2018; 27: 748
        • Oktay K
        • Harvey BE
        • Partridge AH
        • et al.
        Fertility preservation in patients with cancer: ASCO clinical practice guideline update.
        J Clin Oncol. 2018; 36: 1994
        • Borini A
        • Bianchi V
        Cryopreservation of mature and immature oocytes.
        Clin Obstet Gynecol. 2010; 53: 763
        • Donnez J
        • Dolmans MM
        Cryopreservation and transplantation of ovarian tissue.
        Clin Obstet Gynecol. 2010; 53: 787
        • Bromer JG
        • Patrizio P
        Fertility preservation: the rationale for cryopreservation of the whole ovary.
        Semin Reprod Med. 2009; 27: 465
        • Pacheco F
        • Oktay K
        Current success and efficiency of autologous ovarian transplantation: a meta-analysis.
        Reprod Sci. 2017; 24: 1111
        • Practice Committee of the American Society for Reproductive Medicine
        Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.
        Fertil Steril. 2019; 112: 1022-1033
        • Nahata L
        • Woodruff TK
        • Quinn GP
        • et al.
        Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?.
        J Assist Reprod Genet. 2020; 37: 1323-1326
        • Demeestere I
        • Simon P
        • Englert Y
        • Delbaere A
        Preliminary experience of ovarian tissue cryopreservation procedure: alternatives, perspectives, and feasibility.
        Reprod Biomed Online. 2003; 7: 572-579
        • Donez J
        • Manavella DD
        Dolmans MM: Techniques for ovarian tissue transplantation and results.
        Minerva Ginecol. 2018; 70: 424-431
        • Soldin OP
        • Hoffman EG
        • Waring MA
        • Soldin SJ
        Pediatric reference intervals for FSH, LH, estradiol, T3, free T3, cortisol, and growth hormone on the DPC IMMULITE 1000.
        Clin Chim Acta. 2005; 355: 205-210
        • Visser JA
        • de Jong FH
        • Laven JS
        • Themmen AP
        Anti-Mullerian hormone: a new marker for ovarian function.
        Reproduction. 2006; 131: 1-9
        • ACOG Committee Opinion No 605
        Primary ovarian insufficiency in adolescents and young women.
        Obstet Gynecol. 2014; 123: 193-197
        • Nelson LM
        Primary ovarian insufficiency.
        N Engl J Med. 2020; (360): 606-614
        • Demeestere I
        • Simon P
        • Emiliani S
        • et al.
        Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease.
        Oncologist. 2007; 12: 1437-1442
        • Lass A
        The fertility potential of women with a single ovary.
        Hum Reprod Update. 1999; 5: 546
        • Bjelland EK
        • Wilosz P
        • Tanbo TG
        • et al.
        Is unilateral oophorectomy associated with age at menopause? A population study (the HUNT2 survey).
        Hum Reprod. 2014; 29: 835-841
        • Leiper A
        • Houwing M
        • Davies EG
        • et al.
        Anti-Müllerian hormone and inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens.
        Bone Marrow Transplant. 2020; 55: 1985-1995
        • Schmidt KT
        • Andersen CY
        Recommendations for fertility preservation in patients with lymphomas.
        J Assist Repro Genet. 2012; 29: 473-477
        • Revel A
        • Davis VJ
        Casper RF: Ovarian cortex cryopreservation in pediatric and adolescent medicine.
        J Pediatr Adolesc Gynecol. 2000; 13: 95
        • Poirot C, Brugieres L, Yakouben K,
        • et al.
        Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of age facing highly gonadotoxic treatment. Twenty years of experience at a single center.
        Acta Obstet Gynecol Scand. 2019; 98: 630-637
        • Fallat ME
        • Hutter J
        The Committee on Bioethics, Section on Hematology/Oncology, and Section on Surgery. Preservation of fertility in pediatric and adolescent patients with cancer.
        Pediatrics. 2008; 121: e1461-e1469
      1. Practice Committee of American Society for Reproductive Medicine: Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.
        Fertil Steril. 2013; 100: 1214-1223
        • Rowell EE
        • Corkum KS
        • Lautz TB
        • et al.
        Laparoscopic unilateral oophorectomy for ovarian tissue cryopreservation in children.
        J Pediatr Surg. 2019; 54: 543-549
      2. Children's Oncology Group: Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, Version 4.0 Monrovia, CA. 2013. Available: www.survivorshipguidelines.org. Accessed October 23, 2018

        • George SA
        • Lewis RW
        • Shirmer DA
        • et al.
        Early detection of ovarian dysfunction by anti-Mullerian hormone in adolescent and young adult-aged survivors of childhood cancer.
        J Adolesc Young Adult Oncol. 2018; https://doi.org/10.1089/jayao.2018.0080
        • van Dorp W
        • van den Heuvel-Eibrink MM
        • de Vries AC
        • et al.
        Decreased serum anti-Mullerian hormone levels in girls with newly diagnosed cancer.
        Hum Reprod. 2014; 29: 337-342
        • Rosendahl M
        • Andersen CY
        • Ernst E
        • et al.
        Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study.
        Hum Reprod. 2008; 23: 2475-2483
        • Krawczuk-Rybak M
        • Leszczynska E
        • Poznanska M
        • et al.
        Anti-Mullerian hormone as a sensitive marker of ovarian function in young cancer survivors.
        Int J Endocrinol. 2013; 125080
        • Lunsford AJ
        • Whelan K
        • McCormick K
        • McLaren JF
        Anti-Mullerian hormone as a measure of reproductive function in female childhood cancer survivors.
        Fertil Steril. 2014; 101: 227-231
        • Elchuri SV
        • Patterson BC
        • Brown M
        • et al.
        Low anti-Mullerian hormone in pediatric cancer survivors in the early years after gonadotoxic therapy.
        J Pediatr Adolesc Gynecol. 2016; 29: 393-399
        • Morarji K
        • McArdle O
        • Jui K
        • et al.
        Ovarian function after chemotherapy in young breast cancer survivors.
        Curr Oncol. 2017; 24: e494-e502
        • Schmidt KLT
        • Andersen CY
        • Loft A
        • et al.
        Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation.
        Hum Reprod. 2005; 20: 3539-3546